Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ptc Therapeutics (PTCT) Research & Development: 2011-2024

Historic Research & Development for Ptc Therapeutics (PTCT) over the last 14 years, with Dec 2024 value amounting to $534.5 million.

  • Ptc Therapeutics' Research & Development fell 37.95% to $100.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $446.9 million, marking a year-over-year decrease of 15.85%. This contributed to the annual value of $534.5 million for FY2024, which is 19.82% down from last year.
  • According to the latest figures from FY2024, Ptc Therapeutics' Research & Development is $534.5 million, which was down 19.82% from $666.6 million recorded in FY2023.
  • In the past 5 years, Ptc Therapeutics' Research & Development registered a high of $666.6 million during FY2023, and its lowest value of $477.6 million during FY2020.
  • Moreover, its 3-year median value for Research & Development was $651.5 million (2022), whereas its average is $617.5 million.
  • As far as peak fluctuations go, Ptc Therapeutics' Research & Development soared by 85.53% in 2020, and later dropped by 19.82% in 2024.
  • Over the past 5 years, Ptc Therapeutics' Research & Development (Yearly) stood at $477.6 million in 2020, then grew by 13.20% to $540.7 million in 2021, then climbed by 20.49% to $651.5 million in 2022, then rose by 2.31% to $666.6 million in 2023, then dropped by 19.82% to $534.5 million in 2024.